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Membrane-linked sialidase Neu3 is a key enzyme for the extralysosomal catabolism of gangliosides. In this respect, it
regulates pivotal cell surface events, including trans-membrane signaling, and plays an essential role in carcinogenesis. In
this report, we demonstrated that acute lymphoblastic leukemia (ALL), lymphoblasts (primary cells from patients and cell
lines) are characterized by a marked down-regulation of Neu3 in terms of both gene expression (230 to 40%) and enzymatic
activity toward ganglioside GD1a (225.6 to 30.6%), when compared with cells from healthy controls. Induced overexpression
of Neu3 in the ALL-cell line, MOLT-4, led to a significant increase of ceramide (166%) and to a parallel decrease of
lactosylceramide (255%). These events strongly guided lymphoblasts to apoptosis, as we assessed by the decrease in Bcl2/
Bax ratio, the accumulation of Neu3 transfected cells in the sub G0–G1 phase of the cell cycle, the enhanced annexin-V
positivity, the higher cleavage of procaspase-3. Therefore, the reduced expression of Neu3 in ALL could help lymphoblasts to
survive, maintaining the cellular content of ceramide below a critical level. Interestingly, we found that Neu3 activity varied in
relation to disease progression, increasing in clinical remission after chemotherapy, and decreasing again in patients that
relapsed. In addition, a negative correlation was observed between Neu3 expression and the percentage of the ALL marker 9-
OAcGD3 positive cells. Consequently, Neu3 could represent a new potent biomarker in childhood ALL, to assess the efficacy
of therapeutic protocols and to rapidly identify an eventual relapse.
Acute lymphoblastic leukemia (ALL) is a malignant transfor-
mation of lymphoblasts, representing the single commonest
type of cancer in pediatric population. With current treat-
ment protocols, the threat of relapse remains, and about 20%
patients in remission may harbor residual leukemic blasts
defined as minimal residual disease (MRD).1 The sophisti-
cated technical expertise required to detect MRD constrains
its overall clinical acceptance. Therefore, identification of new
biochemical markers is still in demand, whose varied expres-
sion could be utilized for monitoring individual chemothera-
peutic response and predicting impending relapse.
Sialic acids generally found as the terminal sugar of glycan
chain attached to cell surface glycoproteins and glycolipids as
well as secreted glycoconjugates.2,3 Frequent O-acetylations at
positions C-7, C-8 or C-9 of sialic acids generate a family of
O-acetylated sialoglycoconjugates4 and associated with many
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diseases5–8 including cancer cells.9–12 They play an important
role in modulating various biological and pathological proc-
esses including adhesion, signaling, differentiation, apoptosis
and malignancy.12–20
Earlier we have demonstrated enhanced O-acetylation of
sialic acid producing a few ALL-associated 9-O-acetylated sia-
loglycoproteins (Neu5,9Ac2GPs)
12,21–23 and glycolipids19 on
lymphoblasts and erythrocytes,24 not on normal peripheral
blood mononuclear cells (PBMC) or other hematological dis-
orders. In addition, many tumors are characterized by a dif-
ferent composition of glycosphingolipids, particularly ganglio-
sides, i.e., sphingolipids containing sialic acid.25 On these
bases, several sialoglycoconjugates,26–28 their antibodies29,30
and enzymes31 involved in their metabolism could reasonably
be used as suitable markers in ALL and to identify MRD.
Recently, an ever-increasing interest has been devoted to
the study of sialidases in diseased condition. Sialidases cleave
sialic acid residues from glycoconjugates and therefore are
key enzymes in the catabolism of glycoproteins and glyco-
lipids. In mammalian cells, they have been so far classified
into 4 groups (Neu1, Neu2, Neu3 and Neu4) differing in
their subcellular localization and enzymatic property.32 These
4 sialidases behave differently during carcinogenesis.33 In
particular, the membrane-associated sialidase, Neu3 because
of its unique localization in membrane lipid rafts and strict
substrate specificity toward gangliosides34 is involved in the
regulation of cell growth and differentiation via modulation
of cell surface gangliosides. Alterations of Neu3 expression
have been demonstrated to play a pivotal role in
carcinogenesis.35,36
Here, we demonstrated that; (a) a significant decrease in
membrane-associated sialidase Neu3 expression in lympho-
blasts from peripheral blood (PB) and bone marrow (BM) of
patients and ALL-cell lines in comparison to healthy PBMC
(b) a negative correlation could be traced between Neu3
expression and the severity of the disease; (c) the expression
of Neu3 in BM could be followed to monitor the progression
of the disease and the response to a clinical treatment and
(d) Neu3 overexpression through transfection guided lym-
phoblasts toward apoptosis, suggesting that reduced Neu3 in
ALL may help neoplastic cells to survive.
Material and Methods
Chemicals
20-(4-methylumbelliferyl)-a-D-N-acetylneuraminic acid (4-
MU-NeuAc), 4-methylumbelliferone (MU) and 3,30-diamino-
benzidine (DAB) were from Sigma (St. Louis, MO).
[3-3H]sphingosine was from Perkin Elmer (Waltham, MA);
[3H]GD1a were prepared by dichloro-dicyano-benzoquinone/
sodium boro[3H]hydride method followed by reverse phase
HPLC purification.37 Anti-Neu3 antibody was the kind gift
from Dr. Stamatos M. Nicholas, University of Maryland
Medical Center, Baltimore, MD. All PE and Cy5 conjugated
lineage-specific monoclonal antibodies were from BD Phar-
mingen (San Diego, CA).
Patient samples
The study involved clinically confirmed ALL patients at diag-
nosis of disease (10 males, 5 females, median age: 6 years,
range: 0.8–16 years). A few children (n ¼ 10) were longitudi-
nally monitored during chemotherapy. The diagnosis was
established by cytological examination of the bone marrow
(BM) smears according to the French-American-British
Group recommendations, belonging to L1 or L2.
Each sample was immunophenotyped by FACS analysis
using PE and Cy5 conjugated commercially available
Mabs.22,26 They were B-(CD19þ and CD10þ, n ¼ 11) and T-
(CD3þ, CD7þ, n ¼ 4)-ALL. Additionally, FITC-conjugated
affinity purified lectin, Achatinin-H38 was used for detection
of the ALL-associated biomarker, namely Neu5,9Ac2-GPs
on lymphoblasts of these patients for clinical confirma-
tion.11,12,26–28 High level of anti-Neu5,9Ac2-GPs antibodies in
the sera further confirmed their diagnosis.29,30
The samples were collected at Kothari Medical Sciences,
sent to the Indian Institute of Chemical Biology. The samples
were assayed at diagnoses, clinical remission and during clini-
cal relapse. Normal age matched healthy individuals (n ¼ 10)
of both sexes served as controls.
PBMC from venous blood (3–4 ml) and/or lymphoblasts
from BM of patients were separated by density centrifugation
(Ficoll-Hypaque, Amersham Pharmacia, Sweden), washed
thoroughly at 4C and processed within 2–12 hr of collec-
tion. The Institutional Human Ethical Committee had
approved the study and samples were taken with the consent
of the donors, patients, or their parents or guardians.
Cell culture
B-(ALL-PO, REH) and T-(MOLT-4) ALL cell lines were cul-
tured in RPMI-1640 medium supplemented with heat-inacti-
vated FCS [10% (v/v)], L-glutamine (0.002 M), antibiotics
and antimycotics (Medium A).39
Transient transfection of Neu3 in MOLT4 cells
MOLT4 cells were plated at 50% confluence in a 6-well plate
in Medium A. They were transfected with Neu3 cDNA
inserted in the pcDNA3.1 expression vector (Invitrogen,
Carlsbad, CA) by the transfection reagent, FuGENE 6
(Roche, Germany) according to the manufacturer’s instruc-
tions. The following day (after 18 hr of transfection, referred
as time 0 in the results section), the transfection mixture was
removed and replaced with fresh medium. Neu3 level was
detected using PE-anti-Neu3 antibody by flow cytometer, as
an indicator of efficiency of transfection. Neu3 transfected
and mock-transfected cells were further cultured for 48 hr
and the effects on cell death and cell cycle were monitored.
Preparation of cytosol, membrane and lysosomal fractions
Cells were washed with cold phosphate buffer saline contain-
ing 8.1 mM Na2HPO4, 1.5 mM KH2PO4, 2.7 mM KCl, 137
mM NaCl, pH-7.4 (PBS), resuspended in cold PBS with prote-
ase inhibitors (1 lg/ml pepstain A, 10 lg/ml apoprotinin, 10
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lg/ml leupeptin) and lysed by sonication (3 pulse for 8 sec
and giving break for 1 min). The supernatant obtained after
centrifugation at 800g for 10 min at 4C corresponded to
crude cell extract31 and was subsequently centrifuged at
100,000g for 30 min at 4C. Supernatant was used as cytosol.39
The pellet containing the membrane fraction was dissolved in
ice cold PBS. Protein was estimated by the method of Lowry.40
Additionally, lysosomal membranes were prepared by ho-
mogenizing these cells (1  108) in 0.25 M sucrose in 20
mM Tris/HCl (pH 7.2) in a glass homogenizer.41 Suspension
was spun at 800g for 10 min at 4C and the supernatant was
diluted in 0.25 M sucrose in 0.4 M KCl (pH 7.0) and span at
11,000g for 20 min at 4C. The pellet was resuspended in
0.025 M sucrose and allowed to swell for 30 min on ice and
spun at 11,000g for 20 min at 4C. Finally, supernatant was
spun at 100,000g for 1 hr and pellet was suspended in PBS.
In this preparation, b-galactosidase activity was 2-fold
higher over the crude homogenate and negligible activity was
observed in cytosolic fraction indicating that lysosomes had
not been disrupted.
Sialidase assay
The sialidase activity in cytosol, membrane and lysosomal
fractions was determined by using a fluorimetric assay with
4-MU-Neu5Ac (30 nmole) as a substrate, at pH 4.6 for mem-
brane (20 lg) and lysosomal fractions (20 lg) and at pH 5.6
for cytosol (100 lg)34 and a radiochemical assay by using 60
nmole GD1a (containing 0.04 lCi [3H]GD1a) at pH 4.6 for
membrane fractions.34
The kinetics (KM and Vmax) of sialidases (20 lg, as source
of enzyme) was studied by incubating them with various con-
centration of 4-MU-Neu5Ac and [3H]GD1a separately at
37C for 1 hr in sodium acetate buffer (50 mM, pH 4.6 for
membrane and lysosomal sialidases, pH 5.6 for cytosolic siali-
dase). Enzymatic activity was expressed as lmoles or nmoles
of product per hour/mg protein.31
Genetic expression of Neu3
Semi-quantitative RT-PCR. Total RNA was extracted using
RNeasy mini kit (Qiagen, Valencia, CA) and treated with an
RNase free DNase I (Invitrogen) following the manufacturer’s
instruction. First strand cDNA was synthesized by ImProm-
II-Reverse transcription system (Promega, Madison, WI)
according to manufacturer’s protocol.
Semi-quantitative RT-PCR was performed on PTC-100,
(MJ Research, GMI Ramsey, MN) using PCR Kit (Invitro-
gen). Expression of b-actin housekeeping gene was used to
determine the cDNA yield and to normalize PCR product.
The primers used are reported in Table 1. The PCR reactions
were cycled 40 times after initial denaturation (95C, 10 min)
with the following parameters: denaturation at 94C, 30 sec;
annealing at 58C, 30 sec and extension at 72C, 30 sec; fol-
lowed by 72C, 4 min.
Real time PCR. Quantitative analysis was performed by real-
time PCR using a LightCycler rapid thermal cycler system
(Bio-Rad-Richmond, Richmond, CA) with SYBR Green Jump
Start Ready mix (Sigma), following the manufacturer’s
instruction. The specificity of the reactions was confirmed by
melting curve analysis. b-actin was used as an internal
control.
Flow cytometry
The expression of Neu3 was determined by flow cytometry.
Lymphoblasts were initially permeabilized, fixed by BD Cyto-
fix/CytopermTM solution and washed with BD Perm/Wash
buffer (BD Pharmigen), according to the manufacturer’s pro-
tocol. Cells were incubated with rabbit anti-Neu3, diluted in
BD Perm/Wash buffer, for 1 hr at 4C followed by probing
with PE-anti-rabbit IgG antibodies, fixed in paraformalde-
hyde (1%) and analyzed with a FACS Calibur flow cytometer
(Becton Dickinson, Mountain View, CA). The data were ana-
lyzed with the CellQuestPro software (Becton Dickinson).
For 9-O-AcGD3 detection, cells (1  106) were stained
with anti-9-O-AcGD3 (1:5 dilution) Mab on ice for 1 hr in
dark, washed and probed with FITC-anti-murine IgM for 30
min on ice.19 The cells were then washed, fixed in 1% para-
formaldehyde and acquired by flow cytometer.
Determination of cellular sialic acid
Quantification of sialic acids (%) both in the membrane and
cytosolic fractions (25 lg) from normal PBMC (n ¼ 5) and
ALL-cell lines was performed fluorimetrically by oxidizing
the samples and processed using the acetylacetone method.42
The relative fluorescence intensity [kmax(excitation ¼ 410nm)/
kmax(emission ¼ 510nm)] of each sample was measured against
reagent blanks on a Hitachi F-4010 spectrofluorimeter
(Tokyo, Japan). The sialic acid content was determined from
a standard curve obtained using pure sialic acid.
Table 1. Primers used for gene expression
Gene Forward primer Reverse primer
b-actin 50CGACAGGATGCAGAAGGAAG30 50ACATCTGCTGGAAGGTGGA30
Neu3 50TGAGGATTGGGCAGTTGG30 50CCCGCACACAGATGAAGAA30
Neu1 50CCTGGATATTGGCACTGAA30 50CATCGCTGAGGAGACAGAAG30
Neu2 50AGAAGGATGAGCACGCAGA30 50GGATGGCAATGAAGAAGAGG30
Neu4 50TGAGCTCTGCAGCCTTCC30 50GTTCATGGACCGGTGCTC30
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Radio labeling of gangliosides and neutral glycolipids by
[3-3H]sphingosine
[3-3H]sphingosine dissolved in methanol was transferred into
a sterile glass tube and dried under a nitrogen stream. The
residue was then dissolved in prewarmed (37C) culture me-
dium to obtain a final concentration of 3 108 M (corre-
sponding to 0.4 lCi/well). The cells (2  106) were incubated
in presence of [3-3H]sphingosine for 2 hr pulse, followed by
a 24 hr chase, a condition warranting a steady-state meta-
bolic condition. The sphingolipid pattern was determined.34
Analysis of Neu3-transfected cells for apoptosis by
flow cytometry
Neu3-transfected cells were centrifuged, washed twice in PBS,
suspended in annexin-V binding buffer (10 mM HEPES, 140
mM NaCl, 2.5 mM CaCl2, pH 7.4) and stained with FITC-
Figure 1. Sialidase expression in primary cells from clinically confirmed B- and T-ALL patients. (a) Sialidase activity in the lysosomal,
cytosolic and membrane fractions from patients with B-( ) (n ¼ 11) and T-ALL ( ) (n ¼ 4), at presentation of disease, was measured by flu-
orimetric method using MU-Neu5Ac as substrate.34 Fluorescence emission was measured on Fluorimeter (Perkin Elmer, LS55) with excitation
at 365 nm and emission at 450 nm. The enzyme activity of normal PBMC (h) has been shown for comparison. Significance: ***p < 0.001.
(b)Sialidase activity in the membrane fractions from lymphoblasts of peripheral blood (PB) and bone marrow (BM) of B-(n ¼ 11 ) and T-(n ¼
4 ) ALL patients was measured by radiometric method taking [3H]GD1a as substrate.34 The lipids were extracted and analyzed by radio-TLC.
The enzyme activity of PBMC from normal PB has been shown for comparison. Significance: ***p < 0.001. (c) Primary cells from a representa-
tive B-ALL patient, at presentation of disease, and PBMC of a normal individual were incubated with rabbit anti-Neu3 antibodies and
detected by using PE conjugated anti-rabbit IgG antibody, as described in ‘‘Material and methods.’’ Cells were washed, fixed and permeabil-
ized, and the presence of Neu3 was detected by FACS analysis. Comparison was shown as mean fluorescence intensity. (d) The presence of
Neu3 in the primary cells of a representative B-ALL patient, at presentation of disease, and PBMC of a normal individual was analyzed by
Western blot analysis using anti-Neu3 antibody. (e) The genetic expression of Neu3 was measured by quantitative real-time PCR in normal
PBMC (n ¼ 10) and ALL patients (n ¼ 15). The data was normalized against the genetic expression of b-actin. Significance: ***p < 0.001.
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annexin-V and propidium iodide as per manufacturer’s
instructions. Cells were then incubated for 30 min in dark at
20–25C and analyzed as described earlier.
Cell cycle analysis
The cell cycle status of Neu3-transfected cells was analyzed
using Cycle TEST PLUS kit (BD Pharmigen) according to
the manufacturer’s instruction and the percentage of cells in
different phases of cell cycle was determined.
Data analysis
Data analysis was performed using the Graph-Pad Prism sta-
tistics software program (Graph-Pad Software, San Diego,
CA). Results are expressed as mean 6 SD for individual sets
of experiments. Each experiment was performed 4 to 5 times,
and the results are representative of each set of experiment.
Statistical analysis of data was performed using two-tail
student t-test.
Error bars represent standard error of mean (SEM). ***
represents the p < 0.001 considered statistically significant.
The correlation coefficient was determined between individ-
ual Neu3 activities and Neu3 mRNA level of patients and
percentage of 9-O-AcGD3þ cells present in lymphoblasts
along with normal PBMC.
Results
Sialidase expression in primary cells from ALL patients
Lymphoblasts were immunophenotyped as B-(CD19þ and
CD10þ) and T-(CD3þ and CD7þ)-ALL. A high number of
Neu5,9Ac2-GPs
þ (>80% vs. 5–8% normal PBMC) cells were
revealed. They were also typified by an elevated content of
9-O-AcGD3 (þ81%) in comparison to healthy PBMC.19
Enhanced levels of 9-O-AcGD3, irrespective of their lineages,
were always higher than disialoganglioside GD3 in the lym-
phoblasts compared to normal cells.19 Thus, it may be envis-
aged that the O-acetylation machinery is upregulated in
ALL.11,12
We assayed sialidase activity in lysosomes, cytosol and
membrane fractions of lymphoblasts from T- and B-ALL
patients. A marked decrease of sialidase activity associated to
Figure 2. Membrane sialidase activity and expression in ALL-cell lines. (a) The activity of sialidase in the membrane fraction from B-(REH,
ALLPO), T-(MOLT4) ALL-cell lines and normal PBMC (N) was measured by fluorimetric method taking MU-Neu5Ac as substrate, as described
in ‘‘Material and methods.’’ Additionally, sialidase activity was measured by radiometric method taking [3H]GD1a as substrate, as
described in ‘‘Material and methods.’’ Significance: ***p < 0.001. (b) The genetic expression of Neu3 was measured by quantitative real-
time PCR using respective cDNA from normal PBMC (N, n ¼ 10), T- and B-ALL-cell lines. The genetic expression data shown were
normalized against the genetic expression of b-actin. Significance: ***p < 0.001. (c) Neu3 mRNA level in a representative ALL-cell lines
(ALL) and a representative healthy normal PBMC (N) was evaluated by semi-quantitative RT-PCR. The expression of b-actin was also
measured as an internal control for normalization Neu3 expression.
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the plasma membrane (51 to 53%) toward 4-MUNeu5Ac
in lymphoblasts in comparison to healthy PBMC was
observed. In contrast, cytosolic sialidase activity showed an
increase (þ49.5 to 60.4%) and lysosomal sialidase activity
remain unchanged in lymphoblasts (Fig. 1a). We further con-
firmed the decrease of membrane sialidase activity (almost
29.9 to 30.6%) in lymphoblasts using ganglioside
[3H]GD1a, a preferred substrate for sialidase Neu3 (Fig. 1b).
No significant difference in sialidase activity was observed in
membrane fractions between PB and BM lymphoblasts of
these patients (Fig. 1b).
Then, we analyzed the status of sialidase Neu3 on healthy
and patient’s cells by flow cytometry and confirmed that the
decrease of membrane sialidase associated activity was related
to a decrease of the sialidase Neu3. In fact, mean fluorescence
intensity, due to the binding of anti-Neu3 antibody, was 16-
fold lower in lymphoblasts compared with normal PBMC
(Fig. 1c). In addition, Neu3 protein was 30% lower in patients
compared with normal as confirmed by Western blot (Fig.
1d). Accordingly, a 40% reduction in Neu3 gene expression
was observed in patients by real-time PCR (Fig. 1e).
Sialidase expression in ALL-cell lines
As we revealed a reduced expression of Neu3 sialidase in pri-
mary lymphoblasts, we further checked our finding in several
ALL-cell lines. A significant decrease in sialidase activity
(51.06 to 52.3%) was also found in membrane fractions of
cell lines, compared with normal PBMC, toward 4-
MUNeu5Ac (Fig. 2a). The employment of ganglioside GD1a
confirmed this trend (25.6 to 26.6%) (Fig. 2a). Concord-
antly, a decrease in Neu3 gene expression (30%) was
observed in these cell lines (Figs. 2b and 2c), in comparison
to healthy PBMC.
Instead, no significant differences in sialidase activity in
lysosomal fractions between healthy PBMC and ALL-cell
lines were observed; whereas, in cytosolic fractions, sialidase
Figure 3. Sialidase (Neu1, Neu2 and Neu4) activity and expression and sialic acid content in ALL-cell lines. (a) Sialidase activity in the
lysosomal and cytosolic fractions from B-ALL ( ), T-ALL ( ) cell lines and normal PBMC (h) was measured by fluorimetric method taking
MU-Neu5Ac as substrate, as described in ‘‘Material and methods.’’ Significance: ***p < 0.001. (b) Real-time PCR analysis of Neu1, Neu2 and
Neu4 was performed using respective cDNA from ALL-cell lines (n), and normal PBMC (h, N, n ¼ 5). The genetic expression data shown
were normalized against the expression of b-actin. Significance: ***p < 0.001. (c) Genetic expression of Neu1, Neu2 and Neu4 was evaluated
by semi-quantitive RT-PCR and using respective cDNA from a representative ALL-cell line and a representative normal PBMC (N). The expres-
sion of b actin was also measured as an internal control for normalization of the other genes. Significance: ***p < 0.001. (d) Quantification
of sialic acid (Neu5Ac) by fluorimetric estimation using acetylacetone method. Lysate (15 lg), membrane and cytosolic protein (25 lg) from
normal (n) and ALL cells (h) were used for quantification as described in ‘‘Material and methods.’’ Significance: ***p < 0.001.
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activity was doubled (Fig. 3a). Then, the mRNA expression
of sialidases (Neu1, Neu2 and Neu4) revealed a significant
increase (4.4-fold) in Neu2 gene expression (Fig. 3b) in cell
lines compared with normal PBMC. No such difference was
observed in Neu1 expression while Neu4 expression
decreased slightly in ALL cells (Figs. 3b and 3c).
Comparison of kinetic constants of Neu2 and Neu3
between ALL-cell lines and normal PBMC
The reduced expression of Neu3 protein resulted in a
decreased enzymatic activity in ALL-cell lines compared with
normal. In fact, the Vmax of membrane sialidase activity was
30.87 6 2.09 and 58.7 6 3.73 nmole/hr  mg protein in the
membrane fraction of ALL-cell lines and normal PBMC,
respectively, using MU-Neu5Ac as substrate. Accordingly, hy-
drolysis of GD1a by membrane-associated sialidase was
much lower in all types of ALL cells. In fact, the Vmax value
was 1.3-fold less in ALL-cell lines (1.92 lmole/hr  mg pro-
tein) compared with normal (2.5 lmole/hr  mg protein). In
contrast, higher sialidase activity in cytosolic fraction of ALL
cells was observed, Vmax being 15.1 6 1.05 nmole/hr  mg
protein vs. 7.32 6 1.67 nmole/hr  mg protein/min, respec-
tively, using MU-Neu5Ac as a substrate. KM values of mem-
brane and cytosolic sialidases remained unchanged both in
Figure 4. Transfection of Neu3 in MOLT-4 cells and cell cycle analysis. (a) MOLT-4 cells were transfected with Neu3 cDNA, as described in
‘‘Material and methods.’’ The transfection efficiency was measured by flow cytometry, determining the expression of Neu3 protein by using
PE conjugated anti-Neu3 antibody. (b) Mock-transfected and Neu3 transfected MOLT-4 cells were analyzed for cell cycle at different times
after transfection. The cells were analyzed through FACS analysis after propidium iodide staining. Gates were set to assess % of cells in
Sub G0–G1 (<2n DNA, M1), G1 (2n DNA, M2), S (>2n DNA, M3) and G2þM (4n DNA, M4). Bars denote the boundaries of cell cycle
phases.
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normal and ALL, in the range of 3–4  104 M (data not
shown).
Total sialic acid content of ALL-cell lines and normal PBMC
A slight decrease of total sialic acid (15%) was revealed in
ALL-cell lines in comparison to normal PBMC. This may be
due to the fact that more than 42% of sialic acids are O-ace-
tylated in the lymphoblasts of ALL in comparison to normal
PBMC.21 No significant differences in membrane sialic acid
content were observed, being 152 6 6 and 160 6 8 lg/mg
protein in the membrane fraction of normal and ALL cells.
In contrast, the cytosolic fraction showed a decrease by 46%
of sialic acids in ALL cells compared with normal, being 52
6 4 and 96 6 5 lg/mg protein, respectively (Fig. 3d).
Induction of apoptosis in Neu3 transfected MOLT-4 cells
To understand the effects of the reduced expression of Neu3
in the pathogenesis of ALL, we introduced the Neu3 gene
into a representative T-ALL-cell line (MOLT-4). After tran-
sient transfection, a 9.8-fold increase in Neu3 protein level
was observed (Fig. 4a), in comparison to mock cells. Neu3
activity toward GD1a increased by 2.5-fold in transfected
cells in comparison to mock cells (data not shown).
Transfected cells were further analyzed for cell cycle (Fig.
4b). Time 0 hr was considered the time when transfection mix-
ture was removed. First, we assessed a marked reduction of the
proliferation rate, explained by the slowing down of the pro-
gression from the G1 phase to the S phase after 48 hr of trans-
fection. Moreover, importantly, the population in the sub G0–
G1 phase (apoptotic cells) was significantly increased in Neu3-
transfected cells compared with mock cells, after 24 hr of trans-
fection (6.32%) and above all, after 48 hr of transfection reach-
ing 19.10% of the cells. Therefore, the induction of apoptosis
was confirmed as annexin-V positivity increased to 6.79%, af-
ter 0 hr and to 22.32% after 24 hr of Neu3-transfection (mock
cells: 1.01%) (Figs. 5a and 5b). In contrast, as expected the per-
centage of annexin-Vþ/PIþ increased gradually to 7.53% after
48 hr of Neu3-transfection (mock cells: 0.03%). These results
indicate that Neu3 overexpression induced an increased sus-
ceptibility of MOLT-4 cells toward apoptosis.
Figure 5. Analysis of apoptosis in transfected MOLT-4 cells: externalization of phosphatidylserine and apoptosis regulating molecules
analysis. (a) Transfected MOLT-4 cells were stained with FITC-annexin-V and propidium iodide (PI). The percentage of apoptosis (annexinV/
PI) in Neu3 transfected and mock-transfected cells have been shown in dot plot at different times after transfection. (b) The percentage of
annexin-Vþ, annexin-VþPIþ and only PIþ in Mock-transfected and Neu3 transfected cells at different time after transfection was plotted. (c)
Expression of Bcl-2, Bax and active caspase3 in the cell lysate was determined by Western blot analysis using anti-Bax (1:100), anti-Bcl-2
(1:100) and anti-active-caspase3 (1:100) antibodies. Fold decrease /increase was determined when compared with cell only.
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Expression of apoptosis related molecule in Neu3
transfected MOLT-4 cells
To verify the role of Neu3 in apoptosis induction, we eval-
uated the expression of a few apoptosis governing molecules,
Bcl-2, Bax and caspase 3, in Neu3-transfected cells. After 24
and 48 hr of transfection, Western blot analysis showed a
sharp increase in Bax expression while Bcl-2 level decreased,
and then also Bcl-2/Bax ratio decreased (Fig. 5c). Possibly,
these events drove MOLT-4 cells toward death. Consistent
with the results of Bcl-2/Bax above, the cleavage level of pro-
caspase-3 was found to be higher in Neu3-transfected cells af-
ter 24 and 48 hr (Fig. 5c).
Sphingolipid pattern of normal PBMC and
transfected MOLT-4
To identify a molecular connection between Neu3 overex-
pression in MOLT-4 and the events illustrated earlier, we
examined the modifications that occurred in sialoglycosphin-
golipids. The sphingolipid pattern was explored through a
metabolic labeling with [3-3H]sphingosine, after a 2 hr pulse
and a 24 hr chase. Ganglioside pattern of normal PBMC and
mock-transfected MOLT-4 was mainly composed by GM3,
GM1, and GD3 (Figs. 6a and 6b). After Neu3 transfection,
the content of GD3 and GM1 significantly diminished while
GM3, which constitutes the major ganglioside present in
MOLT-4 cells, did not change or slightly increased (Fig. 6b),
in comparison to mock cells.
Neutral glycolipids expressed by mock-transfected MOLT-
4 were very different in comparison to that expressed by nor-
mal PBMC (Fig. 6c). In particular, healthy cells showed a sig-
nificant content of ceramide and the lack of lactosylceramide;
instead, mock-transfected MOLT-4 was characterized by a
marked prevalence of lactosylceramide over ceramide. Never-
theless, Neu3 overexpression gave rise to significant changes
in these cells; lactosylceramide decreased by 55% immediately
after 18 hr of transfection, and ceramide increased by 63%
after 24 hr, and by 66% after 48 hr of transfection (Fig. 6d),
in comparison to mock cells.
Figure 6. Sphingolipid profile of normal PBMC and transfected MOLT-4 cells. (a) HPTLC separation of gangliosides. Doublets are due to the
heterogeneity of the ceramide moiety. Solvent system: chloroform/methanol/0.2% aqueous CaCl2 60:40:9 (v/v). Image acquired by
radiochromatoscanning (Beta Imager 2000). N: normal PBMC. (b) Ganglioside content of normal PBMC (N) and Mock-transfected and Neu3
transfected MOLT-4 cells at different times of transfection. (c) HPTLC separation of neutral glycolipids. Doublets are due to the
heterogeneity of the ceramide moiety. Solvent system: chloroform/methanol/H2O 55:20:3 (v/v). Image acquired by radiochromatoscnning
(Beta Imager 2000). N: normal PBMC. (d) Neutral glycolipid content of normal PBMC and Mock-transfected and Neu3 transfected MOLT-4
cells at different times of transfection.
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Status of Neu3 with disease progression
Ascertained the reduced expression of Neu3 in lymphoblasts
and its connection with apoptosis resistance, we decided to
examine the status of Neu3 activity of lymphoblasts during a
longitudinal follow-up of 10 patients. These patients were
monitored at diagnoses, clinical remission and relapse. In 6
patients, there was a progressive increase in Neu3 activity
being 27% higher between 2 and 40th weeks in clinical
remission when compared with presentation of the disease
(Fig. 7a). In contrast, 4 patients showed decreased Neu3 ac-
tivity at the diagnosis, which progressively increased upto the
18th week and subsequently, decreased again on 30th week
(Fig. 7a). These patients showed clinical symptoms for
relapse at the 32nd week that also reflected on Neu3 activity.
Taken together, these results suggested that decrease of Neu3
activity is strictly associated to ALL and could reasonably
predicted an eventual clinical relapse.
Interestingly, we found a significant correlation between
the Neu3 activity and increased expression of ALL-associated
9-O-AcGD319 both in patients and cell lines. In particular, a
negative correlation between Neu3 activity and the expression
of 9-O-AcGD3 was observed (r2 ¼ 0.95, Fig. 7b). Similarly, a
negative correlation was also observed between Neu3 gene
expression and cell surface expression of 9-O-AcGD3 (r2 ¼
0.84, Fig. 7c).
Discussion
Cancer cells frequently alter the regulation of glycosylation
processes leading to the appearance of characteristic glycosyl-
ated molecules. In particular, ALL lymphoblasts show the
peculiarity to attach O-acetyl group on some sialoglycopro-
teins12,21–23 and sialoglycosphingolipids19 possibly to impair
their catabolism by desialylation, their recognition and ac-
quire an advantage in malignancy.15–20
Here, we demonstrated that lymphoblasts exploit an addi-
tional tool to preserve a particular configuration of glyco-
sphingolipids that help cells to survive. In fact, glycosphingo-
lipids are pivotal components of the plasma membrane
where they can play important roles in modulating signal
transduction processes.25,43,44 An anomalous expression of
some glycosphingolipids is reported as a typical feature in
cancer cells19,25,44 and this event significantly contributes to
alter cell homeostasis and strengthens the malignant behav-
ior, enhancing proliferation, resistance to apoptosis and
invasiveness.45
A key enzyme for the extralysosomal catabolism of sphin-
golipids, through the desialylation of gangliosides, is
Figure 7. Neu3 activity at different phases of therapeutic
treatment. (a) Plot of Neu3 activity determined by using [3H]GD1a
as substrate vs. duration of treatment (weeks). The children (n ¼
10) were longitudinally monitored using membrane fraction (20 lg)
of lymphoblasts from BM. The change of Neu3 activity was
monitored for 90 weeks during treatment. Four patients showed
relapse whereas 6 were in clinical remission. (b) Correlation of
Neu3 activity with the percentage of 9-O-AcGD3þ cells. The Neu3
activity was measured in clinically confirmed ALL patients (n ¼ 15)
at diagnosis, using [3H]GD1a as substrate, as described in
‘‘Material and methods.’’ The percentage of 9-O-AcGD3þ cells was
determined by FACS analysis using monoclonal anti 9-O-ACGD3
antibody as described earlier.19 Correlation plots for ALL patients
(h), ALL-cell lines (l) and normal individuals (n, n ¼ 10) are
shown. The straight line represents regression analysis. (c)
Correlation of Neu3 gene expression with the percentage of 9-O-
AcGD3þ cells. The Neu3 gene expression of clinically and
immunophenotypically confirmed ALL patients (n ¼ 15) was
measured by real-time PCR, as described in ‘‘Material and
methods.’’ The percentage of 9-O-AcGD3þ cells was determined as
described in Figure 7b. Similar correlation plots were obtained for
ALL patients (h), ALL-cell lines (n) and normal individuals (l, n ¼
10). The straight line represents regression analysis.
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undoubtedly the sialidase Neu3.33 Neu3 is localized in lipid
rafts, strictly associated to gangliosides and signal molecules
and is involved in trans-membrane signaling.46,47 Several
reports demonstrated the importance of Neu3 in carcinogen-
esis and evidenced its marked upregulation in some tumors
such as carcinomas and CML.32,34,35,48 In this study, we dem-
onstrated that ALL constitutes an exception in this view. In
fact, we analyzed the expression level of sialidases in lysoso-
mal, cytosolic and membrane fractions of lymphoblasts of
cell lines and primary cells of these patients. A reduced Neu3
expression in terms of mRNA content and enzymatic activity
toward an artificial substrate and gangliosides was detected in
lymphoblasts compared with normal PBMC. This result was
confirmed using several ALL-cell lines. In addition to this
event, a higher expression of the cytosolic sialidase Neu2
characterized ALL cells. This event seems to be related to a
decrease of the intracellular sialic acid content in these lym-
phoblasts in comparison to healthy PBMC, but its connection
with the disease is still obscure and will be object of our
future investigation.
No significant difference of Neu1 and Neu4 expression
between normal PBMC, lymphoblasts and cell lines was
detected, possibly indicating their minimal or negligible
involvement in the disease. Prompted by these results and
aimed to explain the significance of Neu3 downregulation in
ALL, we overexpressed Neu3 in a representative ALL-cell
line, MOLT-4. First, Neu3 overexpression significantly
reduced the proliferation rate, impairing the progression
through the cell cycle. Second but more importantly, this
event pushed MOLT-4 cells toward apoptosis as revealed by
the increase of the population in the sub G0–G1 phase in the
cell cycle and by the annexin-V positivity. In effect, Neu3
overexpression radically altered the main system, which con-
trols apoptosis, increasing the expression of the proapoptotic
protein Bax and decreasing the expression of the anti-apopto-
tic protein Bcl-2. Correspondently, caspase 3 resulted to be
activated. These results are linked to extensive modifications
induced by Neu3 overexpression in the sphingolipid compo-
sition of MOLT-4. Particularly, ceramide was significantly
decreased in lymphoblasts compared with healthy normal
cells while lactosylceramide was abundantly present in lym-
phoblasts, which was completely absent in healthy cells.
These phenomena possibly indicate towards a mechanism of
resistance to apoptosis of lymphoblasts.
To demonstrate the existence of a catabolic process, GD3
disappeared but surprisingly, the cellular content of GM3
slightly modified. This last event could be explained hypothe-
sizing that other enzymes involved in sphingolipid metabo-
lism change their activity, in parallel to Neu3 overexpression;
this occurrence was already established in other cells.34,35,49
Nevertheless, ceramide has been shown to participate in the
activation of the apoptotic process,50 this supports a relation
between the increase of ceramide subsequent to Neu3 overex-
pression and the death by apoptosis. These data contrast
with other studies performed overexpressing Neu3 in colon
adenocarcinoma; in fact, in these cells the high activity of
Neu3 led to an increase of lactosylceramide, not ceramide,
and therefore, enhanced resistance to apoptosis.35 These
results could be related to a complex regulation of the overall
metabolism of sphingolipids and to a different activation of
other enzymes, which are involved in these processes in asso-
ciation to Neu3, in ALL in comparison to other tumors. This
situation is fairly similar to the results obtained after Neu3
overexpression in fibroblasts.49 Therefore, we may conclude
that by downregulating Neu3 expression, ALL cells evolved
the way to survive.
In addition, when we checked Neu3 activity in relation to
disease progression, clinical remission after chemotherapy
and relapse, we found that it effectively changed as the
patient healed or relapsed. In particular, we found that Neu3
activity increased in clinical remission after chemotherapy
and decreased again in patients that relapsed. These results
demonstrated that the reduction of Neu3 is closely linked to
ALL. Thus, Neu3 could represent itself another biomarker in
leukemia. Interestingly, we observed that Neu3 activity var-
ied, along with the percent of 9-OAcGD3 positive cells; in
particularly when Neu3 activity increased, 9-OAcGD3
decreased. This event could be related to a decrease of GD3,
induced by Neu3, as demonstrated by overexpression results.
In conclusion, downregulation of Neu3 is an effective strategy
adopted by leukemic cells to escape the increase of ceramide
and thereby enhance their survival; this feature could be fol-
lowed to assess the efficacy of therapeutic protocols in ALL
patients.
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